On the heels of the FDA’s approval of Amyvid, Siemens Healthcare has applied for FDA 510(k) approval for syngo.PET Amyloid Plaque neurology quantification software. The software may be paired with Amyvid and Siemens biograph mCT PET/CT to comprise an integrated diagnostic imaging system for the detection of amyloid plaques in the living brain
The FDA has approved Amyvid, a radioactive diagnostic agent from Eli Lilly and Avid Radiopharmaceuticals that is indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has released biomarker data from studies intended to improve the ability to diagnose and measure the progression of Alzheimer’s disease.
This article discusses the recent updates in Alzheimer’s detection using amyloid PET radiotracer 18F-flutemetamol, proteins in the cerebrospinal fluid and blood.
PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, has entered into a commercial agreement with Eli Lilly that grants Siemens PETNET the right to manufacture and distribute Lilly’s molecular imaging agent that is currently under review by the FDA for PET imaging.
A $2 million upgrade to an x-ray analytical device was completed through a collaboration with Eli Lilly's research arm and the U.S. Department of Energy's Argonne National Laboratory.
RSS 
